Medpace (MEDP) Stock Price, News & Analysis

Company Overview

Medpace Holdings, Inc. (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing. By integrating these disciplines under one roof, the company aims to ensure consistency in trial design, execution and data analysis, while maintaining compliance with international regulatory standards.

Founded in 1992 by Dr. August J. Troendle and headquartered in Cincinnati, Ohio, Medpace has expanded its footprint to serve clients around the world. The company operates facilities and offices across North America, Europe, the Asia-Pacific region and Latin America, enabling it to manage global studies and facilitate site activation in diverse regulatory environments.

Under the leadership of founder and chairman Dr. August J. Troendle, Medpace draws on a multidisciplinary team of scientific, medical and regulatory experts. The company’s management emphasizes close collaboration with sponsors, leveraging therapeutic area specialists and regional capabilities to address the unique challenges of each clinical program and advance patient-focused research.

Key Stats

• Today's Range: $422.00 to $445.16
• 50-Day Range: $393.42 to $528.44
• 52-Week Range: $291.28 to $628.92
• Volume: 82,079 shs
• Average Volume: 365,378 shs
• Market Capitalization: $12.71 billion
• P/E Ratio: 27.94
• Dividend Yield: N/A
• Price Target: $467.08
• Consensus Rating: Hold

Medpace Stock Analysis - MarketRank™

Medpace scored higher than 50% of companies evaluated by MarketBeat, and ranked 471st out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Hold

Consensus Rating

Medpace has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 4 buy ratings, 10 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Medpace is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Medpace has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 8.80%

Earnings Growth

Earnings for Medpace are expected to grow by 8.80% in the coming year, from $17.04 to $18.54 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medpace is 27.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medpace is 27.73, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.40.

Price to Earnings Growth Ratio

Medpace has a PEG Ratio of 2.18. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Medpace has a P/B Ratio of 21.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.39% of the float of Medpace has been sold short.

Short Interest Ratio / Days to Cover

Medpace has a short interest ratio ("days to cover") of 5.49.

Change versus previous month

Short interest in Medpace has recently increased by 22.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medpace does not currently pay a dividend.

Dividend Growth

Medpace does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.19

News Sentiment

Medpace has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 32 news articles for Medpace this week, compared to 11 articles on an average week.

Search Interest

Only 3 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

10 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,436,197.00 in company stock.

Percentage Held by Insiders

20.50% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/22/2026
• Today: 5/28/2026
• Next Earnings (Estimated): 7/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:MEDP
• CIK: 1668397
• Web: www.medpace.com
• Phone: (513) 579-9911
• Fax: 513-579-0444
• Employees: 6,200
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Medpace: $467.08
• High Price Target: $582.00
• Low Price Target: $305.00
• Potential Upside/Downside: +5.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $15.91
• Trailing P/E Ratio: 27.87
• Forward P/E Ratio: 26.10
• P/E Growth: 2.18
• Net Income: $451.12 million
• Net Margins: 17.19%
• Pretax Margin: 21.35%
• Return on Equity: 120.89%
• Return on Assets: 24.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $2.53 billion
• Price / Sales: 5.02
• Cash Flow: $17.63 per share
• Price / Cash Flow: 25.22
• Book Value: $20.95 per share
• Price / Book: 21.23

Miscellaneous

• Outstanding Shares: 28,560,000
• Free Float: 22,705,000
• Market Cap: $12.70 billion
• Optionable: Optionable
• Beta: 1.19